Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 1972 Oct;69(10):2910-3.
doi: 10.1073/pnas.69.10.2910.

Inactivator of the third component of complement as an inhibitor in the properdin pathway

Inactivator of the third component of complement as an inhibitor in the properdin pathway

C A Alper et al. Proc Natl Acad Sci U S A. 1972 Oct.

Abstract

Evidence has been obtained that a single protein, known to modulate classical complement activation, also acts as an inhibitor in the properdin or alternate complement pathway. A highly purified inactivator of the third component of complement (C3) from human serum inhibited the proteolysis of Factor B in the properdin system (glycine-rich beta-glycoprotein) by glycine-rich beta-glycoproteinase. The inhibition was by the enzymatic destruction of glycine-rich beta-glycoproteinase activity. The major fragment of C3, C3b, which is the only known substrate of the C3 inactivator, blocked the destruction of glycine-rich beta-glycoproteinase by the C3 inactivator. Thus, in its inhibition of the porperdin pathway, the C3 inactivator destroys both the active form of glycine-rich beta-glycoproteinase and a protein involved in the conversion of the zymogen form of this enzyme (proglycine-rich beta-glycoproteinase) to its active form. The increased susceptibility to infections in a patient homozygous for deficiency of the C3 inactivator demonstrates the biologic significance of this protein.

PubMed Disclaimer

Similar articles

Cited by

References

    1. Anal Biochem. 1966 Apr;15(1):45-52 - PubMed
    1. J Immunol. 1967 Sep;99(3):582-9 - PubMed
    1. J Clin Invest. 1967 Dec;46(12):2021-34 - PubMed
    1. J Immunol. 1968 Apr;100(4):691-8 - PubMed
    1. N Engl J Med. 1970 Feb 12;282(7):350-4 - PubMed

MeSH terms

LinkOut - more resources